Back to News
Market Impact: 0.5
Lilly's Retatrutide Drives Significant Weight Loss And A1C Improvement In Phase 3 Diabetes Study
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Eli Lilly reported Phase 3 TRIUMPH-2 results showing that retatrutide produced substantial weight loss and improved blood-sugar control in adults with obesity or overweight and type 2 diabetes. The positive late-stage data strengthen Lilly's position in the high-growth obesity and diabetes treatment market and could be material for the company's drug-development outlook.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
LLY0.82
More News
- Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial
- Lilly’s Foundayo shows cardiovascular safety in diabetes trial
- Nvidia is approaching a breakout level. Plus, what we want to see from Micron
- Wall Street is closing out a strong quarter. Plus, Lilly's mixed obesity drug trial data
- Adding Lilly’s new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
- Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study